The rising prevalence of cardiovascular diseases, increasing diagnosis of valvular heart conditions, and adoption of minimally invasive procedures are supporting the structural heart devices market. These devices help physicians treat abnormalities involving heart valves and other cardiac structures. Advancements in transcatheter technologies are creating alternatives to conventional open-heart procedures.

The global structural heart devices market was valued at USD 18.6 billion in 2025 and is projected to reach USD 21.1 billion in 2026. By 2033, it is expected to reach USD 51.0 billion, growing at a CAGR of 13.5% from 2026 to 2033.

Download a free sample copy of the Structural Heart Devices market report to understand detailed coverage and inclusions in the final report

Why Minimally Invasive Procedures Are Gaining Ground

Catheter-based interventions are changing the treatment landscape for structural heart diseases. Traditional open-heart surgery can involve longer recovery and greater procedural complexity. Transcatheter procedures allow physicians to reach affected cardiac structures through blood vessels, reducing the need for extensive surgical access in suitable patients.

Transcatheter Aortic Valve Replacement (TAVR) is an important option for severe aortic stenosis. Its use across a broader range of patient risk categories is supporting demand for replacement valves and delivery systems. The prevalence of valvular conditions, particularly among older adults, further reinforces this trend.

The Cardiovascular Research Foundation's PREVUE-VALVE study indicated that approximately 4.7 million people aged 65–85 in the U.S. were living with moderate to severe valvular heart disease. Nearly 54.8 million people worldwide were living with rheumatic heart disease in 2024, highlighting the need for effective cardiac interventions.

Device Innovation Moves Beyond Valve Replacement

Manufacturers are improving valve design, catheter navigation, coronary access, and implantation systems. In October 2024, Medtronic received CE Mark approval for its Evolut FX+ TAVR system. Its coronary access windows are approximately four times larger than those in previous Evolut models, supporting coronary reaccess and catheter maneuverability.

In May 2025, Edwards Lifesciences received U.S. FDA approval for its SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA TAVR systems for patients with severe asymptomatic aortic stenosis. The approval expanded the clinical use of transcatheter valve replacement.

Surgical technologies are evolving as well. In March 2025, Corcym received U.S. FDA approval for an enhanced version of its Perceval Plus sutureless surgical aortic valve. The redesigned device includes laser-cut leaflets and refinements intended to support valve performance.

Go Deeper! Ask Prism AI about the Structural Heart Devices Market.

Which Device Categories Are Driving Demand?

TAVR accounted for the largest market revenue share, at 53.4% in 2025, reflecting wider clinical acceptance and growing use for aortic stenosis.

Surgical Aortic Valve Replacement (SAVR) remains relevant for patients requiring conventional surgery. Improvements in sutureless valve designs and implantation techniques support this category. Mitral repair devices address conditions such as mitral regurgitation, while Left Atrial Appendage Closure (LAAC) devices are used in selected patients with atrial fibrillation to help reduce stroke risk. These technologies broaden the range of treatable structural heart conditions.

Regional Adoption: North America Leads, Asia Pacific Accelerates

North America held 52.5% of market revenue in 2025, supported by advanced healthcare infrastructure, reimbursement systems, specialized cardiac centers, and established medical device manufacturers. The U.S. is an important market for transcatheter procedures and advanced valve technologies.

Asia Pacific is expected to register the fastest CAGR during the forecast period. Increasing healthcare expenditure, expanding hospital infrastructure, and improving access to cardiovascular services are supporting adoption. Awareness of minimally invasive treatment in China, India, Japan, and Australia is also creating opportunities.

Europe benefits from established healthcare systems and increasing use of advanced cardiac interventions. Latin America and the Middle East and Africa are gradually expanding access as investment in cardiac facilities improves.

Cost and Access Remain Key Challenges

High device prices can limit adoption where reimbursement is restricted or specialist facilities are scarce. Complex engineering, advanced materials, and specialized manufacturing contribute to product costs. Transcatheter procedures also require trained clinical teams and dedicated equipment.

Despite these barriers, expanding clinical applications, product development, and investment in cardiac infrastructure are expected to support wider access. Demand for less invasive treatment and improvements in valve technologies are likely to shape the structural heart devices market through 2033.

Request a Sample Report to Explore Detailed Market Insights and Industry Analysis.

Key Structural Heart Devices Companies:

·        Boston Scientific Corporation

·        Medtronic plc

·        Edwards Lifesciences Corporation

·        Abbott Laboratories

·        Biomerics

·        Comed BV

·        LivaNova PLC

·        JenaValve

·        CardioKinetix

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.